VolitionRx Partners with Werfen to Advance Diagnostic Testing for Antiphospholipid Syndrome
TL;DR
VolitionRx's partnership with Werfen provides exclusive commercial rights to leverage their Nu.Q NETs assay for APS testing, potentially capturing a significant market advantage.
VolitionRx's Nu.Q NETs assay detects neutrophil extracellular traps on Werfen's ACL AcuStar platform to identify thrombosis risk in antiphospholipid syndrome patients through clinical validation.
This collaboration could improve diagnosis and monitoring for 4 million APS patients worldwide, enabling better disease management and potentially saving lives through earlier detection.
VolitionRx's epigenetic technology represents the first CE-IVD biomarker being investigated for APS, offering a novel approach to understanding this complex autoimmune disorder.
Found this article helpful?
Share it with your network and spread the knowledge!
VolitionRx Ltd. (NYSE American: VNRX) has announced a significant Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center. The partnership focuses on assessing antiphospholipid syndrome (APS) using Volition's proprietary Nu.Q H3.1 Neutrophil Extracellular Traps (NETs) assay on Werfen's diagnostic platforms. This collaboration represents a strategic move to leverage Werfen's extensive disease knowledge, product development capabilities, regulatory experience, and global installed base of proprietary analyzers.
The agreement marks an important development in the diagnostics field, particularly for APS, a complex autoimmune disorder affecting approximately 4 million people worldwide. Current diagnostic methods typically require two positive antibody tests conducted at least 12 weeks apart, creating delays in diagnosis and treatment initiation. Volition believes its Nu.Q NETs test represents the first CE-IVD biomarker being investigated specifically for APS, potentially offering improved decision-making capabilities and enhanced ongoing patient monitoring.
Early technical achievements have already been demonstrated, with successful transfer of the Nu.Q NETs assay to Werfen's ACL AcuStar platform. Initial results in detecting NETs levels in APS patients have shown encouraging outcomes, prompting further validation efforts and comprehensive clinical utility studies. These studies aim to determine the marker's potential role as a risk indicator for thrombosis in APS patients, which could lead to better management of this complex syndrome.
The partnership aligns with Volition's broader strategy of licensing its proprietary Nu.Q NETs test to large worldwide companies. For Werfen, the collaboration offers the possibility of expanding its portfolio in APS testing, addressing a significant unmet medical need in autoimmune diagnostics. The successful implementation of this technology could transform how healthcare providers diagnose and monitor APS patients, potentially reducing complications and improving long-term outcomes for millions affected by this condition.
Further information about Volition's technologies and research can be found at https://www.Volition.com, while details about BioMedWire's communications services are available at https://www.BioMedWire.com.
Curated from InvestorBrandNetwork (IBN)
